Article Sidebar
Published:
Sep 25, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of c isplatin in combination with paclitaxel for oral cancer and its effect on cellular immunity
Abstract
Purpose: To study the efficacy of cisplatin in combination with paclitaxel in the treatment of oral cancer and its effect on cellular immunity.
Methods: A total of 100 patients with oral cancer, treated in the First Affiliated Hospital of Dalian Medical University from May 2018 to April 2020 were included and evenly allocated to study and control groups. The patients in the study group received cisplatin plus paclitaxel, while the patients in the control group received only cisplatin. The serum levels of T lymphocytes, interleukin (IL) -4, IL-2, and interferon gamma (IFN-γ) were determined.
Results: After treatment, the study group showed significantly higher levels of CD3+, CD4+ and CD4/CD8, but a lower CD8+ level (26.17 ± 2.14 μL). than those before treatment (p < 0.05). The control group was associated with higher post-treatment CD3+, CD4+, CD8+, and CD4/CD8 levels and lower CD8+ levels versus patients in the study group (p < 0.05). The study group showed higher levels of IL-2 and INF-γ, (246.77 ± 13.68 and 1194.62 ± 123.15 pg/mL), respectively, but lower IL-4 levels (392.48 ± 13.25 pg/mL) after treatment than before treatment. Control group was associated with higher post-treatment IL-2 and INF-γ levels and lower IL-4 levels compared to patients in the study group (p < 0.05).
Conclusion: Cisplatin and paclitaxel combination offers a viable treatment alternative for oral cancer, as it enhances patients’ immune function and disease prognosis, regulates inflammatory responses, and promotes patients’ recovery. Further investigations in larger population settings are, however, recommended.
